Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source : NAVIGATE ESUS Trial
BACKGROUND AND PURPOSE: The spectrum of brain infarction in patients with embolic stroke of undetermined source (ESUS) has not been well characterized. Our objective was to define the frequency and pattern of brain infarcts detected by magnetic resonance imaging (MRI) among patients with recent ESUS participating in a clinical trial.
METHODS: In the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), an MRI substudy was carried out at 87 sites in 15 countries. Participants underwent an MRI using a specified protocol near randomization. Images were interpreted centrally by those unaware of clinical characteristics.
RESULTS: Among the 918 substudy cohort participants, the mean age was 67 years and 60% were men with a median (interquartile range) of 64 (26-115) days between the qualifying ischemic stroke and MRI. On MRI, 855 (93%) had recent or chronic brain infarcts that were multiple in 646 (70%) and involved multiple arterial territories in 62% (401/646). Multiple brain infarcts were present in 68% (510/755) of those without a history of stroke or transient ischemic attack before the qualifying ESUS. Prior stroke/transient ischemic attack (P<0.001), modified Rankin Scale score >0 (P<0.001), and current tobacco use (P=0.01) were associated with multiple infarcts. Topographically, large and/or cortical infarcts were present in 89% (757/855) of patients with infarcts, while in 11% (98/855) infarcts were exclusively small and subcortical. Among those with multiple large and/or cortical infarcts, 57% (251/437) had one or more involving a different vascular territory from the qualifying ESUS.
CONCLUSIONS: Most patients with ESUS, including those without prior clinical stroke or transient ischemic attack, had multiple large and/or cortical brain infarcts detected by MRI, reflecting a substantial burden of clinical stroke and covert brain infarction. Infarcts most frequently involved multiple vascular territories. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Stroke - 53(2022), 1 vom: 01. Jan., Seite 45-52 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Mukul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.02.2022 Date Revised 16.02.2022 published: Print-Electronic ClinicalTrials.gov: NCT02313909 Citation Status MEDLINE |
|---|
| doi: |
10.1161/STROKEAHA.120.032976 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330800086 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330800086 | ||
| 003 | DE-627 | ||
| 005 | 20231225212051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/STROKEAHA.120.032976 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330800086 | ||
| 035 | |a (NLM)34538089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Mukul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source |b NAVIGATE ESUS Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2022 | ||
| 500 | |a Date Revised 16.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02313909 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND AND PURPOSE: The spectrum of brain infarction in patients with embolic stroke of undetermined source (ESUS) has not been well characterized. Our objective was to define the frequency and pattern of brain infarcts detected by magnetic resonance imaging (MRI) among patients with recent ESUS participating in a clinical trial | ||
| 520 | |a METHODS: In the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), an MRI substudy was carried out at 87 sites in 15 countries. Participants underwent an MRI using a specified protocol near randomization. Images were interpreted centrally by those unaware of clinical characteristics | ||
| 520 | |a RESULTS: Among the 918 substudy cohort participants, the mean age was 67 years and 60% were men with a median (interquartile range) of 64 (26-115) days between the qualifying ischemic stroke and MRI. On MRI, 855 (93%) had recent or chronic brain infarcts that were multiple in 646 (70%) and involved multiple arterial territories in 62% (401/646). Multiple brain infarcts were present in 68% (510/755) of those without a history of stroke or transient ischemic attack before the qualifying ESUS. Prior stroke/transient ischemic attack (P<0.001), modified Rankin Scale score >0 (P<0.001), and current tobacco use (P=0.01) were associated with multiple infarcts. Topographically, large and/or cortical infarcts were present in 89% (757/855) of patients with infarcts, while in 11% (98/855) infarcts were exclusively small and subcortical. Among those with multiple large and/or cortical infarcts, 57% (251/437) had one or more involving a different vascular territory from the qualifying ESUS | ||
| 520 | |a CONCLUSIONS: Most patients with ESUS, including those without prior clinical stroke or transient ischemic attack, had multiple large and/or cortical brain infarcts detected by MRI, reflecting a substantial burden of clinical stroke and covert brain infarction. Infarcts most frequently involved multiple vascular territories. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909 | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a brain infarction | |
| 650 | 4 | |a embolic stroke | |
| 650 | 4 | |a magnetic resonance imaging | |
| 650 | 4 | |a rivaroxaban | |
| 650 | 4 | |a tobacco use | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Smith, Eric E |e verfasserin |4 aut | |
| 700 | 1 | |a Pearce, Lesly A |e verfasserin |4 aut | |
| 700 | 1 | |a Shoamanesh, Ashkan |e verfasserin |4 aut | |
| 700 | 1 | |a Perera, Kanjana S |e verfasserin |4 aut | |
| 700 | 1 | |a Coutts, Shelagh B |e verfasserin |4 aut | |
| 700 | 1 | |a Damgaard, Dorte |e verfasserin |4 aut | |
| 700 | 1 | |a Ameriso, Sebastian F |e verfasserin |4 aut | |
| 700 | 1 | |a Rha, Joung-Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Modrau, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Byung-Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Messé, Steven R |e verfasserin |4 aut | |
| 700 | 1 | |a Barlinn, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Lambeck, Johann |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Feryal |e verfasserin |4 aut | |
| 700 | 1 | |a Berkowitz, Scott D |e verfasserin |4 aut | |
| 700 | 1 | |a Mundl, Hardi |e verfasserin |4 aut | |
| 700 | 1 | |a Connolly, Stuart J |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, Robert G |e verfasserin |4 aut | |
| 700 | 0 | |a NAVIGATE ESUS MIND MRI Substudy Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Field, T S |e investigator |4 oth | |
| 700 | 1 | |a Stotts, G J |e investigator |4 oth | |
| 700 | 1 | |a Gladstone, D J |e investigator |4 oth | |
| 700 | 1 | |a Phillips, S J |e investigator |4 oth | |
| 700 | 1 | |a Sharrief, A |e investigator |4 oth | |
| 700 | 1 | |a Holmstedt, C |e investigator |4 oth | |
| 700 | 1 | |a Vora, N |e investigator |4 oth | |
| 700 | 1 | |a Wilson, C |e investigator |4 oth | |
| 700 | 1 | |a Coull, B M |e investigator |4 oth | |
| 700 | 1 | |a de Havenon, A |e investigator |4 oth | |
| 700 | 1 | |a Birnbaum, L A |e investigator |4 oth | |
| 700 | 1 | |a Patel, N |e investigator |4 oth | |
| 700 | 1 | |a Hussain, M S |e investigator |4 oth | |
| 700 | 1 | |a Greer, D |e investigator |4 oth | |
| 700 | 1 | |a Chen, S |e investigator |4 oth | |
| 700 | 1 | |a Kittner, S |e investigator |4 oth | |
| 700 | 1 | |a Mehta, D |e investigator |4 oth | |
| 700 | 1 | |a Lowenkopf, T |e investigator |4 oth | |
| 700 | 1 | |a Sawyer, R |e investigator |4 oth | |
| 700 | 1 | |a Babikian, V |e investigator |4 oth | |
| 700 | 1 | |a Zweifler, R |e investigator |4 oth | |
| 700 | 1 | |a Tirschwell, D L |e investigator |4 oth | |
| 700 | 1 | |a Sila, C |e investigator |4 oth | |
| 700 | 1 | |a Zhang, C |e investigator |4 oth | |
| 700 | 1 | |a Hong, K-S |e investigator |4 oth | |
| 700 | 1 | |a Oh, K |e investigator |4 oth | |
| 700 | 1 | |a Heo, J H |e investigator |4 oth | |
| 700 | 1 | |a Bae, H-J |e investigator |4 oth | |
| 700 | 1 | |a Park, M S |e investigator |4 oth | |
| 700 | 1 | |a Kim, J S |e investigator |4 oth | |
| 700 | 1 | |a Chung, C-S |e investigator |4 oth | |
| 700 | 1 | |a Lee, B-C |e investigator |4 oth | |
| 700 | 1 | |a Povedano, G P |e investigator |4 oth | |
| 700 | 1 | |a Martin, J J |e investigator |4 oth | |
| 700 | 1 | |a Bruera, G M |e investigator |4 oth | |
| 700 | 1 | |a Jure, L V |e investigator |4 oth | |
| 700 | 1 | |a Marti-Fabregas, J |e investigator |4 oth | |
| 700 | 1 | |a Naranjo, I C |e investigator |4 oth | |
| 700 | 1 | |a Moreno, J M R |e investigator |4 oth | |
| 700 | 1 | |a Portela, P C |e investigator |4 oth | |
| 700 | 1 | |a Gomis, M |e investigator |4 oth | |
| 700 | 1 | |a Serena, J |e investigator |4 oth | |
| 700 | 1 | |a Christensen, H |e investigator |4 oth | |
| 700 | 1 | |a Christensen, T |e investigator |4 oth | |
| 700 | 1 | |a Knecht, S |e investigator |4 oth | |
| 700 | 1 | |a Endres, M |e investigator |4 oth | |
| 700 | 1 | |a Berrouschot, J |e investigator |4 oth | |
| 700 | 1 | |a Schlachetzki, F |e investigator |4 oth | |
| 700 | 1 | |a Wunderlich, S |e investigator |4 oth | |
| 700 | 1 | |a Kraft, P |e investigator |4 oth | |
| 700 | 1 | |a Guyler, P |e investigator |4 oth | |
| 700 | 1 | |a Veltkamp, R C |e investigator |4 oth | |
| 700 | 1 | |a Burn, M |e investigator |4 oth | |
| 700 | 1 | |a Rashed, K |e investigator |4 oth | |
| 700 | 1 | |a Macleod, M J |e investigator |4 oth | |
| 700 | 1 | |a Canepa, C |e investigator |4 oth | |
| 700 | 1 | |a Selvarajah, J |e investigator |4 oth | |
| 700 | 1 | |a Hargroves, D |e investigator |4 oth | |
| 700 | 1 | |a Behnam, Y |e investigator |4 oth | |
| 700 | 1 | |a Robinson, T G |e investigator |4 oth | |
| 700 | 1 | |a Roveri, L |e investigator |4 oth | |
| 700 | 1 | |a Lembo, G |e investigator |4 oth | |
| 700 | 1 | |a Toni, D S |e investigator |4 oth | |
| 700 | 1 | |a Monzani, V |e investigator |4 oth | |
| 700 | 1 | |a Cavallini, A |e investigator |4 oth | |
| 700 | 1 | |a Popov, D |e investigator |4 oth | |
| 700 | 1 | |a Friedrich, M |e investigator |4 oth | |
| 700 | 1 | |a Minelli, C |e investigator |4 oth | |
| 700 | 1 | |a Moro, C |e investigator |4 oth | |
| 700 | 1 | |a Gagliardi, R J |e investigator |4 oth | |
| 700 | 1 | |a Bacellar, A |e investigator |4 oth | |
| 700 | 1 | |a Mikulik, R |e investigator |4 oth | |
| 700 | 1 | |a Eckstein, J |e investigator |4 oth | |
| 700 | 1 | |a Panczel, G |e investigator |4 oth | |
| 700 | 1 | |a Szegedi, N |e investigator |4 oth | |
| 700 | 1 | |a O'Donnell, M J |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke |d 1970 |g 53(2022), 1 vom: 01. Jan., Seite 45-52 |w (DE-627)NLM000010995 |x 1524-4628 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:45-52 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/STROKEAHA.120.032976 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2022 |e 1 |b 01 |c 01 |h 45-52 | ||